Equity Profile

IRON

Disc Medicine, Inc.

Health CareBiotechnology$2.9B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability and helps investors gauge the company's financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its business and capture market share in the biotechnology sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders. Operating in the health care sector, its work is crucial as it addresses unmet medical needs in a specialized area of medicine.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In Q1-2026, Disc Medicine reported an EPS of -$1.65, which was worse than the expected -$1.55. The stock reacted slightly negatively, declining by 0.07% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially given the company's recent history of missing EPS estimates. The lack of analyst estimates adds uncertainty.

Bull Case

If the company can show improved clinical trial results or better-than-expected EPS, it could signal a turnaround and boost investor confidence.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to provide clear guidance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials can significantly influence investor sentiment and the company's future revenue potential.

Will the EPS show any signs of improvement compared to the previous quarter?

A smaller loss or a surprise profit could indicate that the company is moving in the right direction, which is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for improved clinical trial outcomes, which could lead to a more favorable EPS than expected.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect more volatility than has been seen historically.

The company's recent focus on rare blood disorders may yield breakthroughs that are not yet reflected in analyst estimates.

Key Risk

If the clinical trial updates are positive, it could shift sentiment dramatically, contradicting the cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery against the backdrop of previous earnings misses and the company's ability to execute on its clinical pipeline.

Bull Confirmed If

A reduction in EPS to below -$1.50 would confirm the bull case, indicating improved operational efficiency.

Bear Confirmed If

An EPS worse than -$1.65 would confirm the bear case, suggesting continued financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations, history suggests a potential stock increase of around 0.64% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

If the company misses again, history suggests a potential decline of about 0.64% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials and any new data.
2Management's commentary on cost management and operational efficiency.
3Any guidance on expected revenue growth or new partnerships.
4Insights into the competitive landscape and how Disc Medicine plans to position itself.
5Discussion on potential market opportunities for new therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability and helps investors gauge the company's financial health.

N/A

Revenue Growth

Revenue growth indicates the company's ability to expand its business and capture market share in the biotechnology sector.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IRON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In Q1-2026, Disc Medicine reported an EPS of -$1.65, which was worse than the expected -$1.55. The stock reacted slightly negatively, declining by 0.07% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially given the company's recent history of missing EPS estimates. The lack of analyst estimates adds uncertainty.

Bull Case

If the company can show improved clinical trial results or better-than-expected EPS, it could signal a turnaround and boost investor confidence.

Bear Case

Continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to provide clear guidance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials?

Updates on clinical trials can significantly influence investor sentiment and the company's future revenue potential.

Will the EPS show any signs of improvement compared to the previous quarter?

A smaller loss or a surprise profit could indicate that the company is moving in the right direction, which is crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for improved clinical trial outcomes, which could lead to a more favorable EPS than expected.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect more volatility than has been seen historically.

The company's recent focus on rare blood disorders may yield breakthroughs that are not yet reflected in analyst estimates.

Key Risk

If the clinical trial updates are positive, it could shift sentiment dramatically, contradicting the cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for recovery against the backdrop of previous earnings misses and the company's ability to execute on its clinical pipeline.

Bull Confirmed If

A reduction in EPS to below -$1.50 would confirm the bull case, indicating improved operational efficiency.

Bear Confirmed If

An EPS worse than -$1.65 would confirm the bear case, suggesting continued financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±22.14%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±22.1% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

32.9%

Calls (200)P/C Ratio: 1.00Puts (200)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations, history suggests a potential stock increase of around 0.64% on the first day.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity from management.

Miss

If the company misses again, history suggests a potential decline of about 0.64% on the first day.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials and any new data.
2Management's commentary on cost management and operational efficiency.
3Any guidance on expected revenue growth or new partnerships.
4Insights into the competitive landscape and how Disc Medicine plans to position itself.
5Discussion on potential market opportunities for new therapies.